A 6 week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein E-deficient mice chronically infected with Chlamydia pneumoniae

被引:16
作者
Blessing, E [1 ]
Campbell, LA [1 ]
Rosenfeld, ME [1 ]
Chesebro, B [1 ]
Kuo, CC [1 ]
机构
[1] Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA
关键词
C; pneumoniae; atherosclerosis; hyperlipidaemia; treatment; prevention;
D O I
10.1093/jac/dki128
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To evaluate whether antimicrobial chemotherapy prevents acceleration of atherosclerotic lesion development induced by infection with Chlamydia pneumoniae. Methods: ApoE-deficient mice which develop hyperlipidaemia and atherosclerosis spontaneously were inoculated intranasally with C. pneumoniae. Animals were treated with azithromycin for 6 weeks after the third inoculation and the atherosclerotic lesion areas in the aortic sinus were measured by computer-assisted morphometry. Results: At 12 weeks post-infection, infected untreated animals developed significantly larger lesion areas compared with sham-inoculated controls (8.7 x 10(4) +/- 2.3 x 10(4) mu m(2) versus 5.6 x 10(4) +/- 2.4 x 10(4) mu m(2)). However, there were no differences in lesion size of infected mice treated with azithromycin in comparison with untreated infected controls (11.0 x 10(4) +/- 3.0 x 10(4) mu m(2) versus 8.7 x 10(4) +/- 2.3 x 10(4) mu m(2)). Conclusions: Antibiotic treatment against C. pneumoniae has no beneficial effects on hyperlipidaemia-induced atherosclerosis accelerated by C. pneumoniae in a mouse model.
引用
收藏
页码:1037 / 1040
页数:4
相关论文
共 12 条
[1]   Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice [J].
Blessing, E ;
Campbell, LA ;
Rosenfeld, ME ;
Chough, N ;
Kuo, CC .
ATHEROSCLEROSIS, 2001, 158 (01) :13-17
[2]   Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice [J].
Blessing, E ;
Lin, TM ;
Campbell, LA ;
Rosenfeld, ME ;
Lloyd, D ;
Kuo, CC .
INFECTION AND IMMUNITY, 2000, 68 (08) :4765-4768
[3]  
Campbell L.A., 1998, Clin Microbiol Infect, V4 Suppl 4, pS23
[4]   Antibiotic treatment of atherosclerotic cardiovascular disease [J].
Grayston, JT .
CIRCULATION, 2003, 107 (09) :1228-1230
[5]   In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae [J].
Kuo, CC ;
Jackson, LA ;
Lee, A ;
Grayston, JT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) :2669-2670
[6]   DEMONSTRATION OF CHLAMYDIA-PNEUMONIAE IN ATHEROSCLEROTIC LESIONS OF CORONARY-ARTERIES [J].
KUO, CC ;
SHOR, A ;
CAMPBELL, LA ;
FUKUSHI, H ;
PATTON, DL ;
GRAYSTON, JT .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (04) :841-849
[7]   CHLAMYDIA-PNEUMONIAE (TWAR) [J].
KUO, CC ;
JACKSON, LA ;
CAMPBELL, LA ;
GRAYSTON, JT .
CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (04) :451-&
[8]   Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice [J].
Moazed, TC ;
Campbell, LA ;
Rosenfeld, ME ;
Grayston, JT ;
Kuo, CC .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :238-241
[9]   Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model [J].
Muhlestein, JB ;
Anderson, JL ;
Hammond, EH ;
Zhao, LP ;
Trehan, S ;
Schwobe, EP ;
Carlquist, JF .
CIRCULATION, 1998, 97 (07) :633-636
[10]   Azithromycin for the secondary prevention of coronary heart disease events - The WIZARD study: A randomized controlled trial [J].
O'Connor, CM ;
Dunne, MW ;
Pfeffer, MA ;
Muhlestein, JB ;
Yao, L ;
Gupta, S ;
Benner, RJ ;
Fisher, MR ;
Cook, TD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (11) :1459-1466